Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics (BNGO) will host a conference call and webcast on March 23, 2021, at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end financial results for 2020. The company will also highlight recent corporate advancements. Participants can join the call by dialing the provided toll-free or international numbers. Bionano provides genome analysis tools via its Saphyr system, aimed at enhancing genetic research and diagnostics.

Bionano Genomics (BNGO) announced that Praxis Genomics received DEX Z-codes from Palmetto MolDX for its complete menu of laboratory developed tests (LDTs) based on the Saphyr system. These codes enhance clarity for payers regarding molecular diagnostics tests and could accelerate claim payments. Praxis is the first CAP-accredited lab in the U.S. to offer LDTs based on whole genome analysis with Saphyr, potentially leading to Medicare and private insurance reimbursement for optical genome mapping (OGM) tests. Bionano aims to improve the Saphyr system's throughput to 17,000 samples annually by mid-2023.

Bionano Genomics (Nasdaq: BNGO) announced that its CEO, Erik Holmlin, will present virtually at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 2:10 PM EST. The presentation will be accessible via a live webcast on Bionano's Investors section and will be archived for 30 days post-event. Bionano specializes in genome analysis tools, particularly through its Saphyr system, which aids in structural variation detection for genetic research.

Bionano Genomics (BNGO) announced its participation in the 2021 Advances in Genome Biology and Technology (AGBT) meeting, showcasing its Saphyr System for optical genome mapping. The virtual conference, held from March 1-3, will feature presentations from leading institutions, including Boston Children’s Hospital and Harvard Medical School, focusing on psychiatric disorders and cancer.

Key activities include a plenary talk on pediatric psychiatric disorders and various poster presentations. Bionano's CEO and CMO will also participate in a live interview during the conference.

Bionano Genomics announced a significant contribution of its optical genome mapping (OGM) technology to a study published in Science, unveiling thousands of large structural variant calls not captured by traditional methods. The study showcased 64 haplotype-resolved genomes, enhancing understanding of human genetic diversity. OGM identified 5,590 large structural variants, crucial for understanding genetic disorders. This advancement underscores OGM's role in genome analysis, urging researchers to integrate structural data for deeper insights into genetic variation.

Bionano Genomics announced the publication of a study from its Lineagen team that introduces a groundbreaking scoring algorithm called NeuroSCORE. This model evaluates nearly all protein-coding genes for their potential to cause central nervous system (CNS) disorders. By integrating this with the Saphyr platform, the company enhances its diagnostic capabilities. NeuroSCORE combines data from multiple databases, allowing for better identification of variants of unknown significance (VUS) and potentially discovering novel genes linked to conditions like autism spectrum disorder.

Bionano Genomics (Nasdaq: BNGO) will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021, at 1:30 PM PST. CEO Erik Holmlin will participate in a fireside chat. A live webcast can be accessed on Bionano’s Investors website and will be archived for 30 days. Bionano specializes in genome analysis and diagnostic testing through its Saphyr system and Lineagen business, focusing on autism spectrum disorder and other neurodevelopmental disabilities.

Bionano Genomics has announced a significant study showcasing the effectiveness of its Saphyr system for analyzing solid tumors. Conducted by Dr. James Broach, the research demonstrated that Saphyr can detect structural variants (SVs) in various cancer types, including breast and lung cancers. The findings reveal the system's ability to isolate high-quality DNA and identify important cancer gene variants, potentially facilitating targeted therapies. This development opens new avenues for cancer diagnostics and treatment, enhancing Saphyr's role in oncology.

Bionano Genomics (Nasdaq: BNGO) has initiated a pilot program for its Saphyr system at the University Health Network's Laboratory Medicine Program in Toronto, Canada's largest hospital diagnostic lab. This program aims to enhance cancer diagnostics by employing optical genome mapping (OGM) to improve the detection of chromosomal abnormalities and reduce costs. With UHN performing 25 million tests annually, this collaboration represents a significant step forward in streamlining cytogenomic analysis and potentially transforming cancer diagnosis.